# Conversion Therapy Using TACE/HAIC With Anti-Angiogenic and Immunotherapy for Initially Unresectable Hepatocellular Carcinoma Achieving Complete Response or Resectability, Followed by Surgery or Continued Systemic Treatment: A Prospective Cohort Study

> **NCT07206511** · — · NOT_YET_RECRUITING · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 278 (estimated)

## Conditions studied

- Unresectable Hepatocellular Carcinom

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07206511
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10-09
- **Primary completion:** 2028-06-30
- **Final completion:** 2028-12-31
- **Target enrollment:** 278 (ESTIMATED)
- **Last updated:** 2025-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07206511

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07206511, "Conversion Therapy Using TACE/HAIC With Anti-Angiogenic and Immunotherapy for Initially Unresectable Hepatocellular Carcinoma Achieving Complete Response or Resectability, Followed by Surgery or Continued Systemic Treatment: A Prospective Cohort Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07206511. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*